Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
57 stopped studies mapped to Skin Carcinoma and descendants · 98% state a reason
Over the 57 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically… | Phase 2 | withdrawn | May 25, 2025 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in… | Phase 2 | suspended | Jun 29, 2025 | National Cancer Institute (NCI) | Other - planned analysis of safety and efficacy data | Safety / toxicity |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk… | Phase 1 | withdrawn | Aug 3, 2025 | Ankyra Therapeutics, Inc | Strategic realignment | Sponsor / business decision |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck… | Phase 2 | terminated | Nov 8, 2021 | University of California, Davis | Slow accrual | Enrollment / accrual |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | N/A | terminated | Oct 9, 2018 | OHSU Knight Cancer Institute | The study did not meet its accrual goals due to the departure of study personnel. Study team opted… | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05956795 | Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous… | — | terminated | Jul 21, 2023 | Johns Hopkins University | Expired in IRB | Other (stated, no rule matched) |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With… | Phase 1 / Phase 2 | terminated | Jun 4, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or… | Phase 1 | terminated | Nov 15, 2019 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Phase 1 / Phase 2 | terminated | Apr 3, 2019 | NeoImmuneTech | Strategic decision by sponsor | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT03737721 | The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and…(UNSCARRed) | Phase 2 | terminated | Nov 9, 2018 | AHS Cancer Control Alberta | Loss of Pharma Support | Other (stated, no rule matched) |
| NCT04329221 | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant… | Phase 2 | withdrawn | Apr 1, 2020 | Massachusetts General Hospital | The study was withdrawn due to lack of financial support. | Funding |
| NCT04642287 | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant… | Phase 2 | withdrawn | Nov 24, 2020 | Massachusetts General Hospital | The study was withdrawn due to lack of financial support. | Funding |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell… | Phase 2 | withdrawn | Oct 16, 2024 | University of Florida | Study not moving forward due to upcoming PI departure | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell… | Phase 1 | terminated | Aug 6, 2020 | Shattuck Labs, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04807777 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous… | Phase 2 | terminated | Mar 19, 2021 | Columbia University | Departure of the original investigator | Investigator |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | University of Alabama at Birmingham | COVID-19 pandemic, unable to enroll participants | COVID-19 / pandemic |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental… | Phase 2 | withdrawn | Apr 25, 2024 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | N/A | withdrawn | Jun 9, 2022 | Ohio State University Comprehensive Cancer Center | Funding lapse | Funding |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | Phase 1 / Phase 2 | terminated | Jun 1, 2020 | Ivan Litvinov | Inability to recruit patients/lack of funding | Enrollment / accrual |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | Phase 1 | withdrawn | Feb 15, 2023 | Baptist Health South Florida | PI is leaving institution prior to study opening for accrual. | Enrollment / accrual |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A… | Early Phase 1 | withdrawn | Feb 5, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual | Enrollment / accrual |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients… | Phase 1 | withdrawn | Feb 2, 2022 | Rakuten Medical, Inc. | Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled. | Enrollment / accrual |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer,… | N/A | terminated | Aug 15, 2018 | Roswell Park Cancer Institute | Diagnostic issues | Other (stated, no rule matched) |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment, Innovent Biologics has decided not to… | Sponsor / business decision |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase 2 | terminated | Jan 27, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Lack of Interest | Other (stated, no rule matched) |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | Phase 2 | withdrawn | Aug 2, 2021 | Pega-One S.A.S. | Business decision | Sponsor / business decision |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04681456 | Skin Cancer Oncology Radiation Evidence Registry(SCORER) | — | terminated | Dec 23, 2020 | GenesisCare USA | The study was stopped in order to reconfigure it as a PhaseII/III study | Other (stated, no rule matched) |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated…(Pelican) | Phase 1 | withdrawn | Dec 12, 2018 | Turnstone Biologics, Corp. | insufficient suitable drug supply | Drug supply |
| NCT02867722 | Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast…(DaylightPDT) | N/A | withdrawn | Aug 16, 2016 | Brigham and Women's Hospital | The PI decided to not proceed with the trial due to lack of funding. | Funding |
| NCT02699723 | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | Early Phase 1 | withdrawn | Mar 4, 2016 | Jean Yuh Tang | Logistics | Other (stated, no rule matched) |
| NCT03548610 | Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb… | N/A | withdrawn | Jun 7, 2018 | Brigham and Women's Hospital | None of the screened subjects were interested / eligible for enrollment. | Enrollment / accrual |
| NCT03757663 | UV Dosimetry Feedback in NMSC Patients | N/A | withdrawn | Nov 29, 2018 | University of Colorado, Denver | Study closed | Other (stated, no rule matched) |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | Phase 2 | terminated | Jan 9, 2013 | University of Florida | Poor accrual | Enrollment / accrual |
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of… | Phase 2 | terminated | Apr 4, 2013 | Stanford University | Low accrual | Enrollment / accrual |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | Phase 2 | terminated | Nov 15, 2013 | Nina Bhardwaj | PI discretion, low enrollment | Enrollment / accrual |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | Phase 2 | terminated | Mar 3, 2014 | Icahn School of Medicine at Mount Sinai | Closed by sponsor | Other (stated, no rule matched) |
| NCT02223975 | Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease(Vulval VS) | — | suspended | Aug 22, 2014 | Gloucestershire Hospitals NHS Foundation Trust | Study suspended pending further funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials